Iterum Therapeutics plc

General Information
Business:

 

We are a pharmaceutical company dedicated to developing and commercializing sulopenem to be potentially the first and only oral and intravenous (IV) branded penem available globally. Penems, including thiopenems and carbapenems, belong to a class of antibiotics more broadly defined as ß-lactam antibiotics, the original example of which was penicillin, but which now also includes cephalosporins. Sulopenem is a potent, thiopenem antibiotic delivered intravenously which is active against bacteria that belong to the group of organisms known as gram-negatives and cause urinary tract and intra-abdominal infections. We have successfully developed sulopenem in an oral tablet formulation, sulopenem etzadroxil-probenecid. Both sulopenem product candidates have the potential to be important new treatment alternatives to address growing concerns related to antibacterial resistance without the known toxicities of some of the most widely used antibiotics, specifically fluoroquinolones.

 

Industry: PHARMACEUTICAL PREPARATIONS
Employees: 38
Founded: 2015
Contact Information
Address Block 2 Floor 3, Harcourt Centre, Harcourt Street, Dublin 2, Ireland
Phone Number +353 1 903 8920.
Web Address http://www.iterumtx.com
View Prospectus: Iterum Therapeutics plc
Financial Information
Market Cap $181.5mil
Revenues $0.7 mil (last 12 months)
Net Income $-35.7 mil (last 12 months)
IPO Profile
Symbol ITRM
Exchange NASDAQ
Shares (millions): 6.2
Price range $13.00 - $13.00
Est. $ Volume $80.0 mil
Manager / Joint Managers Leerink Partners/ RBC Capital Markets
CO-Managers Guggenheim Securities/ Needham & Company
Expected To Trade: 5/25/2018
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change